Skip to content


Gavreto (pralsetinib) is a small molecule pharmaceutical. Pralsetinib was first approved as Gavreto on 2020-09-04. It is used to treat non-small-cell lung carcinoma in the USA. The pharmaceutical is active against proto-oncogene tyrosine-protein kinase receptor Ret. In addition, it is known to target vascular endothelial growth factor receptor 2. Gavreto's patent is valid until 2036-11-01 (FDA).
Trade Name Gavreto
Common Name Pralsetinib
Indication non-small-cell lung carcinoma
Drug Class Tyrosine kinase inhibitors
Get full access now